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Abstract 
BACKGROUND: Epithelial cell adhesion molecule (EpCAM) is an adhesion molecule which is expressed on the 
epithelial cells and primarily identified as a tumor marker for carcinoma. In this study, the expression of EpCAM in 
precancerous and cancerous gastric lesions was investigated and then, the association of EpCAM expression with 
the overall survival of patient suffering from gastric carcinoma was evaluated. 
METHODS: 12 gastric carcinoma, 3 dysplasia, and 8 intestinal metaplasia (IM) subjects were taken from the 
department of pathology of Tohid Hospital, Sanandaj, Iran. The diagnosis was made by the expert pathologist. 
Then, the subjects were stained for EpCAM by immunohistochemistry (IHC) and analyzed by the pathologist. 
RESULTS: The data showed that EpCAM was expressed in all of the precancerous and cancerous samples. 
However, 76.4% of carcinoma cells were positive for EpCAM while it was 62.5% and 51.3% for dysplasia and IM, 
respectively. Importantly, it was observed that the expression of EpCAM on gastric cancer was negatively correlated 
with the overall survival of the patients. 
CONCLUSION: In conclusion, it was demonstrated in this study that EpCAM is expressed in gastric carcinoma and 
its expression is negatively correlated with the overall survival of the patients with gastric cancer. 
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Introduction1 
Gastric cancer is the second most common 
cause of cancer mortality worldwide1 and its 
incidence increases after the age of 40 years 
old. The ethnic origin can be a possible risk 
factor for gastric cancer, as its overall survival 
and incidence rates vary in different 
geographic locations, with high incidence in 
East, South, and Central Asia, Central and 
Eastern Europe, and South America, whereas 
the United States has the lowest incidence 




rate.2,3 Gastroesophageal reflux disease (GERD) 
and obesity are the main risk factors for the 
development of proximal tumors, while the 
major risk factor for distal cancers is dietary 
factors and Helicobacter pylori (H. pylori) 
infection.4 In spite of remarkable progress in the 
therapeutic methods and surgical techniques, the 
outcome of patients with gastric cancer is not 
satisfactory.5 Therefore, multimodal therapy 
may be a good option for these patients, albeit 
the lack of effective markers. 
The epithelial cell adhesion molecule 
(EpCAM, CD326) is a 39-42 KDa, 314-amino 
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encoded by the 9-exon gene TACSTD1. This 
glycoprotein comprises a large extracellular 
domain with an epidermal growth factor 
(EGF)-like domain and a putative 
thyroglobulin (TY) domain, a single 
transmembrane region, and a short (26 amino 
acids) cytoplasmic tail. EpCAM belongs to the 
family of adhesion molecules, but cell 
adhesion is not its single role and has many 
other functions including cellular signaling, 
proliferation, cell migration, and 
differentiation.1, 5-7 EpCAM is overexpressed in 
various epithelial cancers and its expression 
has been shown in numerous epithelial 
tissues.8 EpCAM overexpression has been 
revealed in gastric cancers, while it is not 
overexpressed in healthy gastric tissues.9 In the 
majority of cancers, EpCAM expression has 
not a good prognosis, however gastric cancer 
is accompanied by some contradictions.10 In 
this introductory study, EpCAM expression on 
gastric precancerous and cancerous lesions 
were examined. 
Materials and Methods 
Paraffin-embedded tissue samples of 23 cases 
[12 gastric cancers, 3 dysplasia, and 8 intestinal 
metaplasia (IM)] were taken out from the 
archives of the pathology department of Tohid 
Hospital, Sanandaj, Iran. All samples were 
confirmed and staged in the pathology 
department, according to Gleason scores. 
Clinical information was obtained from the 
medical records.10  
Immunohistochemistry (IHC): The blocks 
were cut in 5 µm and after heating at 60 °C for 
1 hour, they were deparaffinized in xylene. 
Then, the blocks were rehydrated in increasing 
grads of ethanol. For antigen retrieval, the 
sample was incubated for 20 minutes at 95 °C 
in citrate buffer and incubated with 0.3% 
hydrogen peroxide for 10 minutes at room 
temperature to block endogenous peroxidase 
activity. After protein blocking with bovine 
serum albumin (BSA) 1% for 5 minutes at 
room temperature, the samples were incubated 
with 1:100 diluted EpCAM primary antibody 
(eBioscience™), at 4 °C for 24 hours. IHC 
staining was performed with a kit (Dako, 
Denmark), according to the manufacturer 
protocol, and hematoxylin was used for 
counterstaining. After mounting, slides were 
examined by a pathologist. Only membranous 
staining was considered for IHC scoring. For 
each tumor sample, staining intensity  
(0, 1+, 2+, and 3+) and percentage of positive 
tumor cells were estimated. Results were 
grouped as follows: negative (total absence of 
staining), weak (1+ staining in <  60% of cells 
or 2+ staining in < 30% of cells), moderate  
(1+ staining in ≥ 60% of cells, 2+ staining in 30% 
to 70%, or 3+ staining in < 30%), and strong  
(2+ staining in > 70% or 3+ staining in ≥ 30%).11 
One way analysis of variance (ANOVA) 
with Tukey’s post-test were used to analyze 
the statistical differences of EpCAM 
expression of IM, gastrointestinal dysplasia 
(GID), and carcinoma. The Kaplan-Meier 
method was exploited for survival curves, 
and P values were calculated using the log-
rank (Mantel-Cox) test. P values < 0.05 were 
considered to be statistically significant. All 
statistical analyses were performed using the 
SPSS software (version 18.0, SPSS Inc., 
Chicago, IL, USA). 
Results 
EpCAM expression: EpCAM expression was 
evaluated in 23 samples containing 12 
carcinomas, 3 GID, and 8 IM. In normal 
gastric tissues of all samples, no EpCAM 
expression was seen, however in all of the 
GID, IM, and carcinomas samples, EpCAM 
overexpression was found. In the carcinoma 
samples, 76.4% of cells were positive for 
EpCAM, whereas in the GID and IM samples, 
this rate was 62.5% and 51.3%, respectively 
(Figure 1). The average staining intensity was 
3+ in more than 80% of carcinoma cells and 2+ 
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Figure 1. Average epithelial cell adhesion 
molecule (EpCAM) positive cells in intestinal 
metaplasia (IM), gastrointestinal dysplasia 
(GID), and carcinoma. Data were represented as 
mean ± standard deviation (SD).  
P < 0.01 IM vs. carcinoma 
 
EpCAM expression and correlation with 
overall survival: Carcinoma samples were 
used to evaluate survival analysis. The 
samples with more than 75% positive cells 
showed a positive association with overall 
survival of patients (Long Rank, P < 0.05). The 
median survival time of patients with elevated 
EpCAM expression was 105 days in 
comparison with samples with lower EpCAM 
expression (45 Days) (Figure 2). 
 





120 <75% EpCAM Positive Cells















Figure 2. Kaplan-Meier survival curve: overall 
survival analysis according to different 
percentages of epithelial cell adhesion molecule 
(EpCAM) positive cells among patients suffering 
from carcinoma. 
Discussion 
EpCAM is an adhesion molecule on the 
epithelial cells that is primarily identified as a 
tumor marker for carcinomas.7,10,12 In this study, 
the EpCAM expression was investigated in 
different stages of gastric cancer in addition to 
the evaluation of the association of EpCAM 
overexpression with overall survival of patients 
with carcinoma. It was observed that EpCAM 
overexpression in all stages of gastric cancer (IM, 
GID, and carcinoma), while its expression in 
early stages, was lower than the advanced stage, 
and staining intensity in the advanced stage was 
more than the early stage. Accordingly, EpCAM 
has an important role in the carcinogenesis of 
gastric cancer. Kroepil et al. identified that in 
gastric cancer, EpCAM overexpression was 
correlated with higher tumor cell proliferation 
and higher lymph node metastasis.5 Moreover, 
Wenqi et al. indicated EpCAM overexpression in 
gastric cancer tissues and cell lines. They 
revealed that EpCAM down regulation leads to 
cell proliferation decline, cell cycle arrest in 
SGC7901 and human gastric adenocarcinoma 
cell line (AGS) cells, and blocked tumor 
formation in nude mice.1 In contrast with the 
results of the present study, Joo et al. revealed 
that EpCAM expression was higher in the early 
stage of gastric cancer.13 
Differences in tissue processing and the use 
of different primary anti-EpCAM antibodies 
may be the likely reasons. EpCAM expression 
was used for the classification of gastric 
cancer5 and as an ideal target for 
immunotherapy.6 
Mukherjee et al. showed that the EpCAM 
was overexpressed in the tumor stroma of 
prostate cancer.14 Yanamoto et al. found 
EpCAM overexpression in squamous cell 
carcinoma (SCC) of the tongue and EpCAM 
expression was related to invasion pattern, 
tumor size, and regional lymph node 
metastasis.15 Pak et al. identified EpCAM 
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Conclusion 
In conclusion, the current results revealed that 
in the early stage of gastric cancer, EpCAM 
expression was increased and its expression 
was elevated with the progress of the tumor. 
However, EpCAM overexpression showed 
lower survival in a patient with carcinoma. 
Nevertheless, it should be taken into account 
that this experiment was carried out on a 
limited number of patients and further studies 
employing a high number of patients  
are required. 
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